Figure legends
Fig 1. Flowchart of patients included in the study.
Fig 2. Cycle-dependent effect of chemotherapy on survival outcomes. A-B: Estimated hazard ratios (HRs) (solid lines) with 95% confidence intervals (dotted line) for the association of chemotherapy cycles with progression-free survival (PFS), and overall survival (OS). A minimal of 5 cycles (indicated by the vertical line) of chemotherapy was identified for reduction of risks disease progress and death. C-D: Long-course chemotherapy with ≥5 cycles outperformed short-course chemotherapy for improving PFS and OS in SCNEC.